Glaukos Announces Retirement Of Olav Bergheim From Board Of Directors

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that Olav B. Bergheim, 65, will retire from the company’s board of directors. Mr. Bergheim, who has been a member of the board since he co-founded Glaukos in 1998, will continue to serve as a director until his current term expires at the company’s Annual Meeting on June 2, 2016.

Back to news